Centering upon the positive overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) results from the phase 3 THOR trial, the FDA approved erdafitinib, an oral selective pan-FGFR tyrosine kinase inhibitor, for the treatment of platinum pre-treated adult patients with FGFR-altered advanced or metastatic urothelial carcinoma.